

Protocol for Coronavirus 19 Vaccines (Moderna, Novavax, Pfizer-BioNTech)

1. What's New

- A. Individuals 6 months and older should receive the 2024-2025 COVID-19 vaccine (Moderna, Novavax, or Pfizer-BioNTech).

2. Immunization Protocol

- A. Administer one or more doses of the updated 2024–2025 Moderna, Novavax, or Pfizer-BioNTech COVID-19 vaccine based on level of immunocompetency, age, and previous vaccination status. See Section 3 for vaccine volume and dosing schedule.
- B. COVID-19 vaccine may be administered concomitantly with other vaccines. There is no need to separate COVID-19 vaccine from other vaccinations by 2 weeks.

3. Vaccine Schedule¹⁻⁶

A. Vaccine Schedule for Immunocompetent Individuals

Table 1A: Immunocompetent Individuals Ages 6 Months through 4 Years*

Note - The [PREP Act, 11th Amendment](#) allows pharmacists to administer COVID-19 vaccines to persons aged 3 through 18 years old through 12/31/2024. Otherwise, pharmacists are only permitted to vaccinate persons ≥ 7 years per ORS 689.645.

COVID-19 Vaccination History Prior to Updated (2024-2025 Formula) Vaccine†	Updated (2024-2025 Formula) Vaccine	Number of Updated (2024-2025 Formula) Vaccine Doses Indicated	Dosage (mL/mcg)	Interval Between Doses
Unvaccinated	Moderna	2	0.25 mL/ 25 mcg	Dose 1 and Dose 2: 4-8 weeks‡
	Pfizer-BioNTech	3	0.3 mL/ 3 mcg	Dose 1 and Dose 2: 3-8 weeks‡ Dose 2 and Dose 3: At least 8 weeks
1 dose any Moderna	Moderna	1	0.25 mL/ 25 mcg	4-8 weeks after last dose‡
2 or more doses any Moderna	Moderna	1	0.25 mL/ 25 mcg	At least 8 weeks after last dose
1 dose any Pfizer-BioNTech	Pfizer-BioNTech	2	0.3 mL/ 3 mcg	Dose 1: 3-8 weeks after last dose‡ Dose 1 and Dose 2: At least 8 weeks

Protocol for Coronavirus 19 Vaccines (Moderna, Novavax, Pfizer-BioNTech)

2 doses any Pfizer-BioNTech	Pfizer-BioNTech	1	0.3 mL/ 3 mcg	At least 8 weeks after last dose
3 or more doses any Pfizer-BioNTech	Pfizer-BioNTech	1	0.3 mL/ 3 mcg	At least 8 weeks after last dose

†COVID-19 vaccination history refers to previous receipt of doses of Original monovalent mRNA or bivalent mRNA vaccine or a combination of the two.

*Per FDA authorization, all COVID-19 vaccine doses in this age group should be homologous. In the following circumstances, an age-appropriate COVID-19 vaccine from a different manufacturer may be administered:

- Same vaccine not available at the vaccination site at the time of the clinic visit
- Previous dose unknown
- Person would otherwise not receive a recommended vaccine dose
- Person starts but unable to complete a vaccination series with the same COVID-19 vaccine due to a contraindication

Table 1B: Immunocompetent Individuals Ages 5 through 11 years[§]

Note - The [PREP Act, 11th Amendment](#) allows pharmacists to administer COVID-19 vaccines to persons aged 3 through 18 years old through 12/31/2024. Otherwise, pharmacists are only permitted to vaccinate persons ≥ 7 years per ORS 689.645.

COVID-19 Vaccination History Prior to Updated (2024-2025 Formula) Vaccine†	Updated (2024-2025 Formula) Vaccine	Number of Updated (2024-2025 Formula) Vaccine Doses Indicated	Dosage (mL/mcg)	Interval Between Doses
Unvaccinated	Moderna	1	0.25 mL/ 25 mcg	-
	OR			
	Pfizer-BioNTech	1	0.3 mL/ 10 mcg	-
1 or more doses any mRNA	Moderna	1	0.25 mL/ 25 mcg	At least 8 weeks after last dose
	OR			
	Pfizer-BioNTech	1	0.3 mL/ 10 mcg	At least 8 weeks after last dose

†COVID-19 vaccination history refers to previous receipt of doses of Original monovalent mRNA or bivalent mRNA vaccine or a combination of the two.

§ For children who transition from age 4 years to age 5 years during the initial vaccination series:

- **Moderna series:** Children are recommended to complete the 2-dose series with the updated 2024–2025 Formula Moderna COVID-19 Vaccine, 0.25 mL/25 mcg (), as per the FDA EUA; there is no dosage change.
- **Pfizer-BioNTech series:** Children who received 1 or 2 doses of Pfizer-BioNTech vaccine for ages 6 months–4 years, 0.3 mL/3 mcg are recommended to receive 1 dose of the updated 2024–2025 Formula Pfizer-BioNTech COVID-19 Vaccine, 0.3 mL/10 mcg on or after turning age 5 years. If the 10 mcg dose is the second dose, administer 3–8 weeks after the first dose; if it is the third dose, administer at least 8 weeks after the second dose. Alternatively, these children may complete the 3-dose series with the updated 2024–2025 Formula Pfizer-BioNTech COVID-19 Vaccine for ages 6 months–4 years, 0.3 mL/3 mcg (as per the FDA EUA).

**Protocol for Coronavirus 19 Vaccines
(Moderna, Novavax, Pfizer-BioNTech)**

Table 1C: Immunocompetent Individuals Ages 12 years and older

COVID-19 Vaccination History Prior to Updated (2024-2025 Formula) Vaccine†	Updated (2024-2025 Formula) Vaccine	Number of Updated (2024-2025 Formula) Vaccine Doses Indicated	Dosage (mL/mcg)	Interval Between Doses
Unvaccinated	Moderna	1	0.5 mL/ 50 mcg	-
	OR			
	Novavax	2	0.5 mL/ 5 mcg rS protein and 50 mcg Matrix-M adjuvant	Dose 1 and Dose 2: 3-8 weeks‡
	OR			
1 or more doses any mRNA; 1 or more doses Novavax or Janssen, including in combination with any Original monovalent or bivalent COVID-19 vaccine doses	Pfizer-BioNTech	1	0.3 mL/ 30 mcg	-
	Moderna	1	0.5 mL/ 50 mcg	At least 8 weeks after last dose
	OR			
	Novavax	1	0.5 mL/ 5 mcg rS protein and 50 mcg Matrix-M adjuvant	At least 8 weeks after last dose
OR				
	Pfizer-BioNTech	1	0.3 mL/ 30 mcg	At least 8 weeks after last dose

†COVID-19 vaccination history refers to previous receipt of doses of Original monovalent mRNA or bivalent mRNA vaccine or a combination of the two; for people ages 12 years and older, original monovalent Novavax COVID-19 Vaccine doses, alone or in combination with any mRNA vaccine doses; and for people ages 18 years and older, Janssen COVID-19 Vaccine doses, alone or in combination with any mRNA or Original monovalent Novavax vaccine doses.

‡ An [8-week interval](#) between the first and second COVID-19 vaccine doses (Moderna, Novavax, and Pfizer-BioNTech) might be optimal for some people as it might reduce the small risk of myocarditis and pericarditis associated with these vaccines.

¶The updated 2024-2025 formula Moderna and Pfizer-BioNTech COVID-19 vaccines are also available in a prefilled, single-dose syringe for individuals 12 years and older.

**Protocol for Coronavirus 19 Vaccines
(Moderna, Novavax, Pfizer-BioNTech)**

B. Vaccine Schedule for Individuals with Moderately or Severely Immunocompromising Conditions

Table 2A: Age 6 months through 4 years with Moderately or Severely Immunocompromising Conditions*

*See section 5a for list of immunocompromising conditions.

Note - The [PREP Act, 11th Amendment](#) allows pharmacists to administer COVID-19 vaccines to persons aged 3 through 18 years old through 12/31/2024. Otherwise, pharmacists are only permitted to vaccinate persons ≥ 7 years per ORS 689.645.

COVID-19 Vaccination History Prior to Updated (2024-2025 Formula) Vaccine†	Updated (2024-2025 Formula) Vaccine	Number of Updated (2024-2025 Formula) Vaccine Doses Indicated‡	Dosage (mL/mcg)	Interval Between Doses
Unvaccinated	Moderna	3	0.25 mL/ 25 mcg	Dose 1 and Dose 2: 4 weeks Dose 2 and Dose 3: At least 4 weeks
	OR			
	Pfizer-BioNTech	3	0.3 mL/ 3 mcg	Dose 1 and Dose 2: 3 weeks Dose 2 and Dose 3: At least 8 weeks
1 dose any Moderna	Moderna	2	0.25 mL/ 25 mcg	Dose 1: 4 weeks after last dose Dose 1 and Dose 2: At least 4 weeks
2 doses any Moderna	Moderna	1	0.25 mL/ 25 mcg	At least 4 weeks after last dose
3 or more doses any Moderna	Moderna	1	0.25 mL/ 25 mcg	At least 8 weeks after last dose
1 dose any Pfizer-BioNTech	Pfizer-BioNTech	2	0.3 mL/ 3 mcg	Dose 1: 3 weeks after last dose Dose 1 and Dose 2: At least 8 weeks
2 doses any Pfizer-BioNTech	Pfizer-BioNTech	1	0.3 mL/ 3 mcg	At least 8 weeks after last dose

Protocol for Coronavirus 19 Vaccines (Moderna, Novavax, Pfizer-BioNTech)

3 or more doses any Pfizer BioNTech	Pfizer-BioNTech	1	0.3 mL/ 3 mcg	At least 8 weeks after last dose
-------------------------------------	-----------------	---	------------------	----------------------------------

†COVID-19 vaccination history refers to previous receipt of doses of Original monovalent mRNA or bivalent mRNA vaccine or a combination of the two.

- †Children ages 6 months through 4 years who are moderately or severely immunocompromised may receive 1 additional dose of a homologous updated 2024–2025 Formula mRNA vaccine at least 2 months after the last updated 2024–2025 mRNA vaccine dose. Further additional homologous updated 2024–2025 mRNA dose(s) may be administered by a pharmacist with a prescription issued by a healthcare provider. Any further additional doses should be administered at least 2 months after the last updated 2024–2025 mRNA vaccine dose. For Moderna, administer 0.25 mL/25 mcg (dark blue cap; green label); for Pfizer-BioNTech, administer 0.3 mL/3 mcg for all doses.
- **Pfizer-BioNTech series:** Children are recommended to receive an updated 2024–2025 Pfizer-BioNTech COVID-19 Vaccine, 0.3 mL/10 mcg for all doses received on or after turning age 5 years. Alternatively, they may complete the 3-dose series with updated 2024–2025 Pfizer-BioNTech COVID-19 Vaccine for ages 6 months–4 years, 0.3 mL/3 mcg

Table 2B: Ages 5 through 11 years with Moderately or Severely Immunocompromising Conditions *

* See section 5a for list of immunocompromising conditions.

Note - The [PREP Act, 11th Amendment](#) allows pharmacists to administer COVID-19 vaccines to persons aged 3 through 18 years old through 12/31/2024. Otherwise, pharmacists are only permitted to vaccinate persons ≥ 7 years per ORS 689.645.

COVID-19 Vaccination History Prior to Updated (2024-2025 Formula) Vaccine†	Updated (2024-2025 Formula) Vaccine	Number of Updated (2024-2025 Formula) Vaccine Doses Indicated±	Dosage (mL/mcg)	Interval Between Doses
Unvaccinated	Moderna	3	0.25 mL/ 25mcg	Dose 1 and Dose 2: 4 weeks Dose 2 and Dose 3: At least 4 weeks
	OR			
	Pfizer-BioNTech	3	0.3 mL/ 10 mcg	Dose 1 and Dose 2: 3 weeks Dose 2 and Dose 3: At least 4 weeks
1 dose any Moderna	Moderna	2	0.25 mL/ 25 mcg	Dose 1: 4 weeks after last dose Dose 1 and Dose 2: At least 4 weeks

**Protocol for Coronavirus 19 Vaccines
(Moderna, Novavax, Pfizer-BioNTech)**

2 doses any Moderna	Moderna	1	0.25 mL/ 25 mcg	At least 4 weeks after last dose
1 dose any Pfizer- BioNTech	Pfizer-BioNTech	2	0.3 mL/ 10 mcg	Dose 1: 3 weeks after last dose Dose 1 and Dose 2: At least 4 weeks
2 doses any Pfizer- BioNTech	Pfizer-BioNTech	1	0.3 mL/ 10 mcg	At least 4 weeks after last dose
3 or more doses any mRNA vaccine	Moderna	1	0.25 mL/ 25 mcg	At least 8 weeks after last dose
	OR			
	Pfizer-BioNTech	1	0.3 mL/ 10 mcg	At least 8 weeks after last dose

†COVID-19 vaccination history refers to previous receipt of doses of Original monovalent mRNA or bivalent mRNA vaccine or a combination of the two.

±Children ages 5–11 years who are moderately or severely immunocompromised may receive 1 additional dose of updated 2024–2025 Moderna COVID-19 Vaccine, 0.25mL/25 mcg or updated 2024–2025 Pfizer-BioNTech COVID-19 Vaccine, 0.3 mL/10 mcg at least 2 months after the last updated 2024–2025 mRNA vaccine dose indicated in Table 2B. Further additional dose(s) may be administered by a pharmacist with a prescription issued by a healthcare provider. Any further additional doses should be administered at least 2 months after the last updated 2024–2025 mRNA vaccine dose.

* For children who transition from age 4 years to age 5 years during the initial vaccination series:

- **Moderna series:** Children are recommended to receive an updated 2024–2025 Moderna COVID-19 Vaccine, 0.25 mL/25 mcg for all doses.
- **Pfizer-BioNTech series:** Children are recommended to receive an updated 2024–2025 Pfizer-BioNTech COVID-19 Vaccine, 0.3 mL/10 mcg for all doses received on or after turning age 5 years. Alternatively, they may complete the 3-dose series with updated 2024–2025 Pfizer-BioNTech COVID-19 Vaccine for ages 6 months–4 years, 0.3 mL/3 mcg (yellow cap; yellow label).

**Protocol for Coronavirus 19 Vaccines
(Moderna, Novavax, Pfizer-BioNTech)**

Table 2C: Ages 12 years and older with Moderately or Severely Immunocompromising Conditions *

*See section 5a for list of immunocompromising conditions.

COVID-19 Vaccination History Prior to Updated (2024-2025 Formula) Vaccine†	Updated (2024-2025 Formula) Vaccine	Number of Updated (2024-2025 Formula) Vaccine Doses Indicated‡§	Dosage (mL/mcg)	Interval Between Doses
Unvaccinated	Moderna	3	0.5 mL/ 50 mcg	Dose 1 and Dose 2: 4 weeks Dose 2 and Dose 3: At least 4 weeks
	OR			
	Novavax	2	0.5 mL/ 5 mcg rS protein and 50 mcg Matrix-M adjuvant	Dose 1 and Dose 2: 3 weeks
	OR			
	Pfizer-BioNTech	3	0.3 mL/ 30 mcg	Dose 1 and Dose 2: 3 weeks Dose 2 and Dose 3: At least 4 weeks
1 dose any Moderna	Moderna	2	0.5 mL/ 50 mcg	Dose 1: 4 weeks after last dose Dose 1 and Dose 2: At least 4 weeks
2 doses any Moderna	Moderna	1	0.5 mL/ 50 mcg	At least 4 weeks after last dose
1 dose any Pfizer-BioNTech	Pfizer-BioNTech	2	0.3 mL/ 30 mcg	Dose 1: 3 weeks after last dose Dose 1 and Dose 2: At least 4 weeks

**Protocol for Coronavirus 19 Vaccines
(Moderna, Novavax, Pfizer-BioNTech)**

2 doses any Pfizer-BioNTech	Pfizer-BioNTech	1	0.3 mL/ 30 mcg	At least 4 weeks after last dose
3 or more doses any mRNA vaccine	Moderna	1	0.5 mL/ 50 mcg	At least 8 weeks after last dose
	OR			
	Novavax	1	0.5 mL/ 5 mcg rS protein and 50 mcg Matrix-M adjuvant	At least 8 weeks after last dose
	OR			
	Pfizer-BioNTech	1	0.3 mL/ 30 mcg	At least 8 weeks after last dose
1 or more doses Novavax or Janssen, including in combination with any Original monovalent or bivalent COVID-19 vaccine doses	Moderna	1	0.5 mL/ 50 mcg	At least 8 weeks after last dose
	OR			
	Novavax	1	0.5 mL/ 5 mcg rS protein and 50 mcg Matrix-M adjuvant	At least 8 weeks after last dose
	OR			
	Pfizer-BioNTech	1	0.3 mL/ 30 mcg	At least 8 weeks after last dose

†COVID-19 vaccination history refers to previous receipt of doses of original monovalent mRNA or bivalent mRNA vaccine or a combination of the two; for people ages 12 years and older, original monovalent Novavax COVID-19 Vaccine doses, alone or in combination with any mRNA vaccine doses; and for people ages 18 years and older, Janssen COVID-19 Vaccine doses, alone or in combination with any mRNA or original monovalent Novavax vaccine doses.

‡Apart from the administration of additional doses, the FDA EUA for the updated 2024–2025 Novavax COVID-19 vaccine does not provide for a specific vaccination schedule for people who are moderately or severely immunocompromised. People ages 12 years and older who are moderately or severely immunocompromised have the option to receive 1 additional dose of an updated 2024–2025 Moderna COVID-19 Vaccine, 0.5 mL/50 mcg an updated 2024–2025 Novavax COVID-19 Vaccine; or an updated 2024–2025 Pfizer-BioNTech COVID-19 Vaccine, 0.3 mL/30 mcg at least 2 months following the last recommended updated 2024–2025 vaccine dose. Further additional dose(s) may be administered by a pharmacist with a prescription issued by a healthcare provider. Any further additional doses should be administered at least 2 months after the last updated 2024-2025 COVID-19 vaccine dose.

§Administration of additional doses is as follows:

- **People ages 12–64 years who are moderately or severely immunocompromised** may receive 1 additional dose of any updated 2024–2025 COVID-19 vaccine (i.e., Moderna, Novavax, or Pfizer-BioNTech) at least 2 months after the last dose of an updated 2024–2025 COVID-19 vaccine as indicated in Table 2C. Pharmacist may administer further additional dose(s) with a prescription issued by a healthcare provider. Any further additional doses should be administered at least 2 months after the last updated 2024–2025 COVID-19 vaccine dose.

Protocol for Coronavirus 19 Vaccines (Moderna, Novavax, Pfizer-BioNTech)

- **People ages 65 years and older who are moderately or severely immunocompromised** should receive 1 additional dose of any updated 2024–2025 COVID-19 vaccine (i.e., Moderna, Novavax, or Pfizer-BioNTech) at least 2 months after the last dose of an updated 2024–2025 vaccine as indicated in Table 2C. Pharmacist may administer further additional dose(s) with a prescription issued by a healthcare provider. Any further additional doses should be administered at least 2 months after the last updated 2024–2025 COVID-19 vaccine dose.
- For all age groups, additional dosing is as follows: Moderna, 0.5 mL/50 mcg; Novavax, 0.5 mL/5 mcg rS protein and 50 mcg Matrix-M adjuvant; Pfizer-BioNTech, 0.3 mL/30 mcg.

¶ The updated 2024–2025 Moderna and Pfizer-BioNTech COVID-19 vaccines are also available in a prefilled, single-dose syringe for people ages 12 years and older.

*For children who transition from age 11 years to age 12 years during the initial vaccination series:

- **Moderna series:** Children are recommended to receive an updated 2024–2025 Moderna COVID-19 Vaccine, 0.5 mL/50 mcg for all doses received on or after turning age 12 years. Alternatively, they may complete the 3-dose series with an updated 2024–2025 Moderna COVID-19 Vaccine for children ages 5–11 years, 0.25 mL/25 mcg.
- **Pfizer-BioNTech series:** Children are recommended to receive an updated 2024–2025 Formula Pfizer-BioNTech COVID-19 Vaccine, 0.3 mL/30 mcg for all doses received on or after turning age 12 years. Alternatively, they may complete the 3-dose series with an updated 2024–2025 Pfizer-BioNTech COVID-19 Vaccine for children ages 5–11 years, 0.3 mL/10 mcg).

4. Licensed Vaccines

Product Name	Vaccine Components	Presentation	FDA Approved Age Range
Pfizer-BioNTech 2024-2025 formulation ¹	mRNA	0.9 mL, 3 dose vial 0.3 mL, single dose vial	3-4 years 5-11 years
Pfizer-BioNTech COMIRNATY ^{®3} 2024-2025 formulation	mRNA	0.3 mL, single dose vial 0.3 mL, prefilled syringe	≥ 12 years
Moderna 2024-2025 formulation ²	mRNA	0.25 mL, single dose vial	3-11 years
Moderna SPIKEVAX [®] 2024-2025 formulation ⁴	mRNA	2.5 mL, 5 dose vial 0.5 mL, single dose vial 0.5 mL, prefilled syringe	≥ 12 years
NVX-CoV2373 ³ (NOVAVAX [®] 2024-2025 formulation) ⁵	Protein subunit	2.5 mL, 5-dose vial	≥ 12 years

5. Recommendations for Use¹⁻⁸

A. Vaccine Schedule for Immunocompetent Individuals

Ages 6 months–4 years

Protocol for Coronavirus 19 Vaccines (Moderna, Novavax, Pfizer-BioNTech)

1. Unvaccinated: 2 or 3 homologous (i.e., from the same manufacturer) updated 2024–2025 mRNA vaccine doses, depending on vaccine manufacturer (i.e., Moderna, Pfizer-BioNTech).
2. Previously received an incomplete series of original monovalent or bivalent mRNA vaccine doses: Complete the vaccination series with 1 or 2 homologous updated 2024–2025 mRNA vaccine doses, depending on vaccine manufacturer and the number of previous vaccine doses.
3. Previously received all doses in the initial vaccination series with original monovalent or bivalent mRNA vaccine: 1 homologous updated 2024–2025 mRNA vaccine dose.
4. Special situations for children ages 6 months–4 years: COVID-19 vaccine doses from the same manufacturer should be administered whenever recommended. In the following circumstances, an age-appropriate COVID-19 vaccine from a different manufacturer may be administered:
 - Same vaccine not available at the vaccination site at the time of the clinic visit
 - Previous dose unknown
 - Person would otherwise not receive a recommended vaccine dose
 - Person starts but unable to complete a vaccination series with the same COVID-19 vaccine due to a contraindication.
5. The **extended interval** consideration applies only to the following people who are not moderately or severely immunocompromised:
 - Ages 6 months–4 years, depending on their vaccination history
 - Ages 12 years–64 years and receiving a 2-dose Novavax seriesThe **minimum interval** between the first and second doses continues to be recommended for:
 - People who are moderately or severely immunocompromised
 - People ages 65 years and older receiving Novavax vaccine
 - Situations when the fullest possible protection needs to be achieved sooner (e.g., increased concern about an individual’s higher risk for severe disease)

Ages 5–11 years

1. Unvaccinated or previously received any number of original monovalent or bivalent mRNA vaccine doses: 1 dose of an updated 2024–2025 mRNA vaccine from either manufacturer (i.e., Moderna or Pfizer-BioNTech).

Ages 12 years and older

1. Unvaccinated: 1 dose of an updated 2024–2025 mRNA COVID-19 vaccine (i.e., Moderna, Pfizer-BioNTech) OR 2 doses of the updated 2024–2025 Novavax vaccine.
2. Previously received 1 or more original monovalent or bivalent mRNA vaccine doses: 1 dose of any updated 2024–2025 COVID-19 vaccine (i.e., Moderna, Novavax, or Pfizer-BioNTech).
3. Previously received 1 or more doses of original monovalent Novavax vaccine, alone or in combination with any original monovalent or bivalent mRNA vaccine doses: 1 dose of any updated 2024–2025 Formula COVID-19 vaccine (i.e., Moderna, Novavax, or Pfizer-BioNTech).
4. Previously received 1 or more doses of Janssen vaccine, alone or in combination with any original monovalent or bivalent mRNA vaccine or Original monovalent Novavax doses: 1 dose of any updated 2024–2025 COVID-19 vaccine (i.e., Moderna, Novavax, or Pfizer-BioNTech).
5. ~~Special situations for people ages 65 years and older: People ages 65 years and older should receive 1 additional dose of any updated 2024–2025 COVID-19 vaccine (i.e., Moderna, Novavax, or Pfizer-BioNTech) at least 4 months following the previous dose of an updated 2024–2025 COVID-19 vaccine. For initial vaccination with the updated 2024–2025 Novavax~~

Protocol for Coronavirus 19 Vaccines (Moderna, Novavax, Pfizer-BioNTech)

~~COVID-19 Vaccine, the 2-dose series should be completed before administration of the additional dose.~~

6. The **extended interval** consideration applies only to the following people who are not moderately or severely immunocompromised:

- Ages 6 months–4 years, depending on their vaccination history
- Ages 12 years–64 years and receiving a 2-dose Novavax series

The **minimum interval** between the first and second doses continues to be recommended for:

- People who are moderately or severely immunocompromised
- People ages 65 years and older receiving Novavax vaccine
- Situations when the fullest possible protection needs to be achieved sooner (e.g., increased concern about an individual’s higher risk for severe disease)

B. Vaccine Schedule for Individuals with Moderately or Severely Immunocompromising Conditions

Conditions causing moderate to severe immunodeficiency include[‡]:

- Active treatment for solid tumor and hematologic malignancies
- Receipt of solid-organ transplant and taking immunosuppressive therapy
- Receipt of Chimeric antigen receptor (CAR)-T-cell or hematopoietic cell transplant (HCT) within 2 years of transplantation or taking immunosuppression therapy
- Moderate or severe primary immunodeficiency (e.g., DiGeorge, Wiskott-Aldrich syndromes)
- Advanced or untreated HIV infection (people with HIV and CD4 cell counts <200/mm³, history of an AIDS-defining illness without immune reconstitution, or clinical manifestations of symptomatic HIV)
- Active treatment with high-dose corticosteroids (i.e., ≥20 mg prednisone or equivalent per day)
- Alkylating agents, antimetabolites, transplant-related immunosuppressive drugs, cancer chemotherapeutic agents classified as severely immunosuppressive, TNF blockers, and other biologic agents that are immunosuppressive or immunomodulatory.

[‡]Individuals with immunocompromising conditions not listed above may receive subsequent vaccination doses with a prescription from a healthcare provider.

Ages 6 months through 4 years

1. Unvaccinated: 3 homologous (i.e., from the same manufacturer) updated 2024–2025 mRNA vaccine doses (i.e., Moderna, Pfizer-BioNTech).
2. Previously received 1 or 2 original monovalent or bivalent mRNA vaccine doses: Complete the 3-dose series with 2 or 1 homologous updated 2024–2025 mRNA vaccine doses, respectively.
3. Previously received a combined total of 3 or more original monovalent or bivalent mRNA vaccine doses: 1 dose of a homologous updated 2024–2025 mRNA vaccine.
4. Special situations for children ages 6 months–4 years: COVID-19 vaccine doses from the same manufacturer should be administered whenever recommended. In the following circumstances, an age-appropriate COVID-19 vaccine from a different manufacturer may be administered:
 - Same vaccine not available at the vaccination site at the time of the clinic visit
 - Previous dose unknown

Protocol for Coronavirus 19 Vaccines (Moderna, Novavax, Pfizer-BioNTech)

- Person would otherwise not receive a recommended vaccine dose
 - Person starts but unable to complete a vaccination series with the same COVID-19 vaccine due to a contraindication.
5. Additional doses: May receive 1 or more additional homologous updated 2024–2025 mRNA vaccine doses with a prescription issued by a healthcare provider.

Ages 5 through 11 years

1. Unvaccinated: 3 homologous (i.e., from the same manufacturer) updated 2024–2025 mRNA vaccine doses (i.e., Moderna, Pfizer-BioNTech).
2. Previously received 1 or 2 original monovalent or bivalent mRNA vaccine doses: Complete the 3-dose series with 2 or 1 homologous updated 2024–2025 mRNA vaccine doses, respectively.
3. Previously received a combined total of 3 or more Original monovalent or bivalent mRNA vaccine doses: 1 dose of an updated 2024–2025 mRNA vaccine from either manufacturer.
4. Additional doses: May receive 1 or more additional updated 2024–2025 mRNA vaccine doses from either manufacturer with a prescription issued by a healthcare provider.

Ages 12 years and older

1. Unvaccinated: 3 homologous (i.e., from the same manufacturer) updated 2024–2025 mRNA vaccine doses (i.e., Moderna, Pfizer-BioNTech) OR 2 updated 2024–2025 Novavax vaccine doses.
2. Previously received 1 or 2 original monovalent or bivalent mRNA vaccine doses: Complete the 3-dose series with 2 or 1 homologous updated 2024–2025 mRNA vaccine doses, respectively.
3. Previously received a combined total of 3 or more original monovalent or bivalent mRNA vaccine doses: 1 dose of any updated 2024–2025 COVID-19 vaccine (i.e., Moderna, Novavax, or Pfizer-BioNTech).
4. Previously received 1 or more original monovalent Novavax vaccine doses, alone or in combination with any original monovalent or bivalent mRNA vaccine doses: 1 dose of any updated 2024–2025 COVID-19 vaccine (i.e., Moderna, Novavax, or Pfizer-BioNTech).
5. Previously received 1 or more doses of Janssen vaccine, alone or in combination with any original monovalent or bivalent mRNA vaccine or original monovalent Novavax doses: 1 dose of any updated 2024–2025 COVID-19 vaccine (i.e., Moderna, Novavax, or Pfizer-BioNTech).
6. Additional doses:
 - People ages 12–64 years may receive 1 or more additional doses of any updated 2024–2025 COVID-19 vaccine (i.e., Moderna, Novavax, or Pfizer-BioNTech) with a prescription issued by a healthcare provider.
 - People ages 65 years and older should receive 1 additional dose of any updated 2024–2025 COVID-19 vaccine (i.e., Moderna, Novavax, or Pfizer-BioNTech) at least 2 months after receipt of a previous updated 2024–2025 COVID-19 vaccine. Individuals 65 years and older may receive further additional doses of any updated 2024–2025 COVID-19 vaccine (i.e., Moderna, Novavax, or Pfizer-BioNTech) with a prescription issued by a healthcare provider.

**Protocol for Coronavirus 19 Vaccines
(Moderna, Novavax, Pfizer-BioNTech)**

6. Contraindications

a. Severe allergic reaction (e.g., anaphylaxis) to a previous dose or to any vaccine component.¹⁻⁵

Vaccine	Contains
Pfizer-BioNTech 2024-2025 formulation ¹	Lipids (0.04 mg ((4-hydroxybutyl)azanediyl)bis(hexane6,1-diyl)bis(2-hexyldecanoate), 0.005 mg 2[(polyethylene glycol)-2000]-N,N itetradecylacetamide, 0.01 mg 1,2-distearoyl-snglycero-3-phosphocholine, and 0.02 mg cholesterol), 9.4 mg sucrose, 0.02 mg tromethamine, and 0.12 mg tromethamine hydrochloride. The diluent (sterile 0.9% Sodium Chloride Injection, USP) contributes 1.88 mg sodium chloride per dose.
Pfizer-BioNTech 2024-2025 formulation ¹	Lipids (0.14 mg ((4- hydroxybutyl)azanediyl)bis(hexane6,1-diyl)bis(2-hexyldecanoate), 0.02 mg 2[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide, 0.03 mg 1,2- distearoyl-sn-glycero-3-phosphocholine, and 0.06 mg cholesterol), 31 mg sucrose, 0.06 mg tromethamine, and 0.4 mg tromethamine hydrochloride.
Pfizer-BioNTech COMIRNATY [®] 2024-2025 formulation ³	Lipids (0.43 mg ((4-hydroxybutyl)azanediyl)bis(hexane6,1-diyl)bis(2-hexyldecanoate),0.05 mg 2-(polyethylene glycol 2000)-N,N-ditetradecylacetamide, 0.09 mg 1,2-distearoyl-snglycero-3-phosphocholine, and 0.19 mg cholesterol), 0.06 mg tromethamine, 0.4 mg tromethamine hydrochloride, and 31 mg sucrose
Moderna 2024-2025 formulation ²	Total lipid content of 0.5 mg (SM-102, polyethylene glycol [PEG] 2000 dimyristoyl glycerol [DMG], cholesterol, and 1,2-distearoyl-sn-glycero-3- phosphocholine [DSPC]), 0.13 mg tromethamine, 0.62 mg tromethamine hydrochloride, 0.011 mg acetic acid, 0.049 mg sodium acetate trihydrate, and 21.8 mg sucrose.
Moderna SPIKEVAX [®] 2024-2025 formulation ⁴	Total lipid content of 1.01 mg (SM-102, polyethylene glycol [PEG] 2000 dimyristoyl glycerol [DMG], cholesterol, and 1,2-distearoyl-sn-glycero-3- phosphocholine [DSPC]), 0.25 mg tromethamine, 1.2 mg tromethamine hydrochloride, 0.021 mg acetic acid, 0.10 mg sodium acetate trihydrate, and 43.5 mg sucrose.
NVA-CoV2373 (NOVAVAX [®] 2024-2025 formulation) ⁵	Cholesterol, phosphatidylcholine, potassium dihydrogen phosphate (3.85 µg), potassium chloride (2.25 µg), disodium hydrogen phosphate dihydrate (14.7 µg), disodium hydrogen phosphate heptahydrate (2.465 mg), sodium dihydrogen phosphate monohydrate (0.445 mg), sodium chloride (8.766 mg) and polysorbate 80 (0.050 mg). The vaccine contains a recombinant form of the SARS-CoV-2 spike protein produced from baculovirus infected Sf9 (fall armyworm) insect cells and Matrix-M [™] adjuvant is composed of Fraction-A (42.5 µg) and Fraction-C (7.5 µg) of saponin extracts from the soapbark tree, Quillaja saponaria Molina. The pH is adjusted with sodium hydroxide or hydrochloric acid.

Protocol for Coronavirus 19 Vaccines (Moderna, Novavax, Pfizer-BioNTech)

7. Warnings and Precautions⁸

- a. History of severe allergic reaction (e.g., anaphylaxis) to any other vaccine or injectable therapy (e.g., intravenous, intramuscular or subcutaneous).
- b. Persons who have a contraindication to additional doses of mRNA COVID-19 vaccines are considered to have a precaution to the Novavax vaccine. A single dose may be given in an appropriate setting under the supervision of a health care provider experienced in the management of severe allergic reactions. Consider referral to an allergist-immunologist. This additional dose could be considered after a minimum interval of 28 days after the mRNA COVID-19 vaccine dose. See Appendix A for additional information.
- c. Moderate or severe acute illness.
- d. Development of myocarditis or pericarditis within 3 weeks after a dose of any COVID-19 vaccine is a precaution to a subsequent dose of any COVID-19 vaccine, and subsequent doses should generally be avoided.

8. Other Considerations⁸

- a. Individuals with known COVID-19 infection should wait until their symptoms have resolved and criteria have been met to discontinue isolation. Persons who have a history of COVID-19 disease should be vaccinated if otherwise indicated. If desired, persons with acute COVID-19 may wait up to 90 days to receive vaccination, as reinfection within 90 days is uncommon. Viral testing to assess for acute SARS-CoV-2 infection or serologic testing to assess for prior infection solely for the purposes of vaccine decision-making is not recommended.
- b. Individuals who received monoclonal antibodies or convalescent plasma during COVID-19 treatment may be vaccinated as soon as their symptoms have resolved.
- c. Individuals with a known community or outpatient setting COVID-19 exposure should wait until the end of their quarantine period before seeking vaccination to avoid potentially exposing healthcare personnel.
- d. Individuals who have been exposed to COVID-19 living in congregate settings, including long-term care, homeless shelters, or correctional institutions, where exposure or transmission can occur repeatedly over a long period of time may be vaccinated without completing a quarantine period.
- e. Ask patient to remain seated in the clinic for 15 minutes after vaccination to decrease the risk of injury should they faint. Individuals with a history of severe allergic reactions should be asked to remain for 30 minutes.
- f. CDC recommends that vaccine for children aged 5–17 years of age with history of Multisystem Inflammatory Syndrome of Children (MIS-C) be delayed for 90 days after their diagnosis of MIS-C. Providers should inform individuals that the risk of reinfection, and therefore the potential benefit from vaccination, may increase with time following initial infection.
- g. COVID-19 vaccination is recommended for all people of childbearing age, including people who are pregnant, breastfeeding, trying to get pregnant now, or might become pregnant in the future.
- h. Persons who are trying to become pregnant do not need to avoid pregnancy after receiving COVID-19 vaccine. There is no recommendation for routine pregnancy testing before receipt of a COVID-19 vaccine.

**Protocol for Coronavirus 19 Vaccines
(Moderna, Novavax, Pfizer-BioNTech)**

- i. Persons with underlying medical conditions who have no contraindications may receive COVID-19 vaccine.
- j. Children 3 years through 4 years of age should complete a multi-dose initial series (2 doses of Moderna vaccine or 3 doses of Pfizer-BioNtech vaccine) with at least one dose of the 2023–2024 COVID-19 mRNA vaccines. Doses for adults and immunocompromised persons ≥5 years of age may receive any age-appropriate authorized product.

9. Side Effects and Adverse Reactions

- a. COVID-19 vaccines appear to be more reactogenic than most. Inform patient that symptoms of immune system activation are normal (see Table) and should improve without intervention in 12-24 hours.

Pfizer-BioNtech^{1,3} and Moderna^{2,4} Adverse Events	Frequency
Injection site events (pain at the injection site, redness, swelling)	Very common, up to 93%
Systemic events (fatigue, headache, muscle ache, joint pain)	Very common, up to 77%
Fever	Up to 16%
Lymphadenopathy*	Up to 20%
Serious adverse events	Uncommon, up to 1% (similar to placebo group)

*Lymph node swelling in the underarm is more common after the booster dose than after the initial series.

Novavax⁵ Adverse Events	Frequency
Injection site events (pain at the injection site, redness, swelling)	Very common, up to 82%
Systemic events (fatigue, muscle pain, headache, nausea)	Very common, up to 62%
Fever	Uncommon, up to 6%

10. Storage and Handling

- a. Store medications according to OAR 855-041-1036.
- b. For Pfizer-BioNtech vaccine only: thaw, if needed.^{1,3}
- c. For Moderna vaccine only: thaw vaccine prior to administration.^{2,4}

Vaccine	Temp	Storage Issues	Notes
Pfizer-BioNtech ^{1,3}	-90° to -60° C (-130° to -76° F)	Vaccine may be stored until the expiration date.	Do not freeze the single dose pre-filled glass syringe (discard if frozen)
	2° to 8° C (36° to 46° F)	Adolescent/adult 2024-2025 formulation: store in the refrigerator for up to 10 weeks	
		Pediatric 2024-2025 formulation: before mixing, the vaccine may be stored in the refrigerator for up to 10 weeks.	

**Protocol for Coronavirus 19 Vaccines
(Moderna, Novavax, Pfizer-BioNTech)**

		Adolescent/adult 2024-2025 formulation Store in the refrigerator until printed expiration date on carton	
	Ambient temperatures	Adolescent/adult 2024-2025 formulation): vaccine may be held at room temperature for up to 12 hours	
		Pediatric 2024-2025 formulation: once mixed, vaccine may be held at room temperature for up to 12 hours	
Moderna ^{2,4}	-50° to -15° C (-58° to 5° F)	Vaccine is viable until the expiration date.	For multi-dose vials, once stopper has been punctured, all doses must be used within 12 hours. Do not refreeze once thawed. Protect vaccine from light.
	2° to 8° C (36° to 46° F)	Vaccine is viable under refrigeration for up to <u>60</u> days.	
	Ambient temperatures	Unpunctured vials of vaccine is viable for up to 24 hours at room temperature	
Novavax ⁵	2°– 8°C (36° to 46° F)	No expiration date is printed on vial or carton. Lookup the expiration date of the batch/Lot number at www.novavaxcovidvaccine.com enter “United States” as the “country/region.”	Once vial stopper has been punctured, store vial at 2° to 25° C (36° to 77° F) for use within 12 hours. Discard the vial 12 hours after first puncture. Do not freeze. Protect vaccine from light.

11. References

1. Pfizer-BioNTech COVID-19 Vaccine, 2024–2025 formulation. Emergency use authorization (EUA) fact sheet, 11 Sep 2023. Available at: <https://www.fda.gov/media/167211/download>.
2. Moderna COVID-19 vaccine, 2024–2025 formulation. Emergency use authorization (EUA) fact sheet and prescribing information, 11 Sep 2023. Available at: <https://www.fda.gov/media/167208/download>.
3. Pfizer-BioNTech Comirnaty, 2024-2025 formulation. Package insert, August 2024. Available at: <https://www.fda.gov/media/151707/download>.
4. Moderna Spikevax, 2024-2025 formulation. Package insert, August 2024. Available at: <https://www.fda.gov/media/155675/download>.
5. Novavax, Inc. Full emergency use authorization (EUA) prescribing information, 3 Oct 2023. Available at: <https://www.fda.gov/media/159897/download>.

**Protocol for Coronavirus 19 Vaccines
(Moderna, Novavax, Pfizer-BioNTech)**

6. Centers for Disease Control and Prevention (2024, August 29). ACIP Vaccine Recommendations and Schedules. Centers for Disease Control and Prevention. Available at: <https://www.cdc.gov/acip/vaccine-recommendations/index.html>
7. Interim clinical considerations for use of COVID-19 vaccines in the United States, September 06, 2024. Available at: <https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html>

12. Appendix

- a. COVID-19 vaccination schedule for people who are not moderately or severely immunocompromised by COVID-19 vaccination history, April 2024: <https://www.cdc.gov/vaccines/covid-19/downloads/covid-19-immunization-schedule-ages-6months-older.pdf>

PROPOSED